Furthermore, FSH has been already addressed as possibly implicated in the postmenopausal changes of bone mineral density [7, 9] and in lipid distribution, adiposity, and metabolism in male patients with hypergonadotropic hypogonadism [8]. The gene discussed is BRD2; the disease is Hypergonadotropic hypogonadism.